PT1740569E - Derivados de imidazole como inibidores de tafia - Google Patents

Derivados de imidazole como inibidores de tafia Download PDF

Info

Publication number: PT1740569E
Authority: PT; Portugal
Prior art keywords: imidazole derivatives; derivatives used; tafia inhibitors; tafia; inhibitors
Prior art date: 2004-04-22

Application number

PT05731221T

Other languages

English (en)

Inventor

Hauke Szillat

Andreas Lindenschmidt

Christopher Kallus

Holger Heitsch

Sven Grueneberg

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-22

Filing date

2005-04-07

Publication date

2008-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1740569(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-04-07 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2008-03-31 Publication of PT1740569E publication Critical patent/PT1740569E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PT05731221T 2004-04-22 2005-04-07 Derivados de imidazole como inibidores de tafia PT1740569E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE102004020186A DE102004020186A1 (de)	2004-04-22	2004-04-22	Heterocyclylessigsäuren als Inhibitoren von TAFla

Publications (1)

Publication Number	Publication Date
PT1740569E true PT1740569E (pt)	2008-03-31

Family

ID=34964308

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT05731221T PT1740569E (pt)	2004-04-22	2005-04-07	Derivados de imidazole como inibidores de tafia

Country Status (34)

Country	Link
EP (2)	EP1740569B1 (pt)
JP (1)	JP4939401B2 (pt)
KR (1)	KR101162047B1 (pt)
CN (1)	CN100572376C (pt)
AR (1)	AR053302A1 (pt)
AT (2)	ATE386737T1 (pt)
AU (1)	AU2005238144B2 (pt)
BR (1)	BRPI0510159A (pt)
CA (1)	CA2563401C (pt)
CR (1)	CR8650A (pt)
CY (1)	CY1108087T1 (pt)
DE (2)	DE102004020186A1 (pt)
DK (1)	DK1740569T3 (pt)
EC (1)	ECSP066941A (pt)
ES (1)	ES2299026T3 (pt)
HR (1)	HRP20080099T3 (pt)
IL (1)	IL178672A (pt)
MA (1)	MA28543B1 (pt)
MY (1)	MY140903A (pt)
NI (1)	NI200600217A (pt)
NO (1)	NO20065320L (pt)
NZ (1)	NZ550757A (pt)
PE (1)	PE20060172A1 (pt)
PL (1)	PL1740569T3 (pt)
PT (1)	PT1740569E (pt)
RS (1)	RS50553B (pt)
RU (1)	RU2375356C2 (pt)
SI (1)	SI1740569T1 (pt)
TN (1)	TNSN06341A1 (pt)
TW (1)	TWI359016B (pt)
UA (1)	UA87306C2 (pt)
UY (1)	UY28868A1 (pt)
WO (1)	WO2005105781A1 (pt)
ZA (1)	ZA200607668B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20150514T1 (hr) *	2006-12-06	2015-09-11	Sanofi	DERIVATI SULFAMIDA KAO INHIBITORI TAFIa
US7638541B2 (en)	2006-12-28	2009-12-29	Metabolex Inc.	5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008100459A1 (en) *	2007-02-13	2008-08-21	Schering Corporation	Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
AU2008279447A1 (en)	2007-07-19	2009-01-29	Metabolex, Inc.	N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
EP2262783A2 (en) *	2008-02-21	2010-12-22	Sanofi-Aventis	Covalently binding imaging probes
CN102056922B (zh)	2008-06-06	2013-11-20	赛诺菲-安万特	作为tafia抑制剂的大环脲和磺酰胺衍生物
JPWO2010050525A1 (ja)	2008-10-29	2012-03-29	大正製薬株式会社	ＴＡＦＩａ阻害活性を有する化合物
BRPI1010571A2 (pt) *	2009-05-15	2019-09-24	Sanofi Sa	processo para a preparação de um composto útil como um inibidor de tafla.
FR2947266B1 (fr) *	2009-06-26	2011-06-17	Servier Lab	Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2011041154A1 (en)	2009-10-01	2011-04-07	Metabolex, Inc.	Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
ES2643132T3 (es) *	2010-03-18	2017-11-21	Daiichi Sankyo Company, Limited	Derivado de imidazol cicloalquilo sustituido
EP2548872B1 (en)	2010-03-18	2016-09-28	Daiichi Sankyo Company, Limited	Cyclopropanecarboxylic acid derivative
EP2638016B1 (en)	2010-11-11	2014-10-01	Sanofi	Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives
US9145385B2 (en)	2011-11-25	2015-09-29	Sanofi	Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexy1-1H-imidazol-4-yl)-propionic acid
US9102657B2 (en) *	2011-11-25	2015-08-11	Sanofi	Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid
WO2013076177A1 (de)	2011-11-25	2013-05-30	Sanofi	Salz von (r)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl)- propionsäureethylester
EP2805705B1 (en)	2013-05-23	2016-11-09	IP Gesellschaft für Management mbH	Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
BR112015029667A2 (pt)	2013-06-10	2017-07-25	Sanofi Sa	derivados de ureia macrocíclica como inibidores de tafia, sua preparação e seus usos como produtos farmacêuticos
US20190117624A1 (en)	2016-03-29	2019-04-25	Daiichi Sankyo Company, Limited	Therapeutic agent for inflammatory bowel diseases
CA3032432A1 (en)	2016-08-03	2018-02-08	Charles A. Mcwherter	Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2292262T3 (es) *	1998-12-24	2008-03-01	Astellas Pharma Inc.	Compuestos de imidazol y su uso medicinal.
WO2003013526A1 (en) *	2001-08-08	2003-02-20	Merck & Co. Inc.	Anticoagulant compounds
MXPA04005940A (es)	2002-01-22	2004-09-13	Pfizer	Acidos 3-(imidazolil)-2-aminopropanoicos.

2004
- 2004-04-22 DE DE102004020186A patent/DE102004020186A1/de not_active Withdrawn
2005
- 2005-04-06 PE PE2005000382A patent/PE20060172A1/es not_active Application Discontinuation
- 2005-04-07 RU RU2006141246/04A patent/RU2375356C2/ru not_active IP Right Cessation
- 2005-04-07 CN CNB2005800115593A patent/CN100572376C/zh not_active Expired - Fee Related
- 2005-04-07 SI SI200530185T patent/SI1740569T1/sl unknown
- 2005-04-07 JP JP2007508756A patent/JP4939401B2/ja not_active Expired - Fee Related
- 2005-04-07 AT AT05731221T patent/ATE386737T1/de active
- 2005-04-07 DE DE502005002927T patent/DE502005002927D1/de not_active Expired - Lifetime
- 2005-04-07 HR HR20080099T patent/HRP20080099T3/xx unknown
- 2005-04-07 PL PL05731221T patent/PL1740569T3/pl unknown
- 2005-04-07 AU AU2005238144A patent/AU2005238144B2/en not_active Ceased
- 2005-04-07 AT AT07017340T patent/ATE523505T1/de active
- 2005-04-07 PT PT05731221T patent/PT1740569E/pt unknown
- 2005-04-07 ES ES05731221T patent/ES2299026T3/es not_active Expired - Lifetime
- 2005-04-07 WO PCT/EP2005/003630 patent/WO2005105781A1/de not_active Ceased
- 2005-04-07 KR KR1020067021881A patent/KR101162047B1/ko not_active Expired - Fee Related
- 2005-04-07 BR BRPI0510159-0A patent/BRPI0510159A/pt not_active Application Discontinuation
- 2005-04-07 EP EP05731221A patent/EP1740569B1/de not_active Expired - Lifetime
- 2005-04-07 RS RSP-2008/0107A patent/RS50553B/sr unknown
- 2005-04-07 DK DK05731221T patent/DK1740569T3/da active
- 2005-04-07 EP EP07017340A patent/EP1864979B1/de not_active Expired - Lifetime
- 2005-04-07 NZ NZ550757A patent/NZ550757A/en not_active IP Right Cessation
- 2005-04-07 CA CA2563401A patent/CA2563401C/en not_active Expired - Fee Related
- 2005-04-20 TW TW094112493A patent/TWI359016B/zh not_active IP Right Cessation
- 2005-04-20 MY MYPI20051748A patent/MY140903A/en unknown
- 2005-04-20 AR ARP050101556A patent/AR053302A1/es not_active Application Discontinuation
- 2005-04-22 UY UY28868A patent/UY28868A1/es unknown
- 2005-07-04 UA UAA200612254A patent/UA87306C2/ru unknown
2006
- 2006-09-13 ZA ZA200607668A patent/ZA200607668B/en unknown
- 2006-09-20 NI NI200600217A patent/NI200600217A/es unknown
- 2006-09-22 CR CR8650A patent/CR8650A/es unknown
- 2006-10-17 IL IL178672A patent/IL178672A/en not_active IP Right Cessation
- 2006-10-19 MA MA29399A patent/MA28543B1/fr unknown
- 2006-10-20 EC EC2006006941A patent/ECSP066941A/es unknown
- 2006-10-20 TN TNP2006000341A patent/TNSN06341A1/en unknown
- 2006-11-20 NO NO20065320A patent/NO20065320L/no not_active Application Discontinuation
2008
- 2008-05-12 CY CY20081100491T patent/CY1108087T1/el unknown

Also Published As

Publication number	Publication date
MY140903A (en)	2010-01-29
IL178672A (en)	2011-08-31
KR101162047B1 (ko)	2012-07-04
CN1950357A (zh)	2007-04-18
UY28868A1 (es)	2005-11-30
RU2375356C2 (ru)	2009-12-10
NO20065320L (no)	2007-01-12
TW200602325A (en)	2006-01-16
EP1864979A1 (de)	2007-12-12
KR20070007346A (ko)	2007-01-15
EP1740569B1 (de)	2008-02-20
ES2299026T3 (es)	2008-05-16
SI1740569T1 (sl)	2008-06-30
JP2007533672A (ja)	2007-11-22
NI200600217A (es)	2008-06-17
RS50553B (sr)	2010-05-07
WO2005105781A1 (de)	2005-11-10
BRPI0510159A (pt)	2007-10-02
EP1864979B1 (de)	2011-09-07
AR053302A1 (es)	2007-05-02
EP1740569A1 (de)	2007-01-10
TNSN06341A1 (en)	2008-02-22
NZ550757A (en)	2010-06-25
DK1740569T3 (da)	2008-06-02
TWI359016B (en)	2012-03-01
PL1740569T3 (pl)	2008-07-31
CN100572376C (zh)	2009-12-23
DE502005002927D1 (de)	2008-04-03
ATE386737T1 (de)	2008-03-15
MA28543B1 (fr)	2007-04-03
DE102004020186A1 (de)	2005-11-17
CR8650A (es)	2007-12-04
HK1101823A1 (zh)	2007-10-26
ATE523505T1 (de)	2011-09-15
AU2005238144B2 (en)	2010-08-26
IL178672A0 (en)	2007-02-11
ZA200607668B (en)	2008-03-26
CA2563401A1 (en)	2005-11-10
ECSP066941A (es)	2006-12-20
JP4939401B2 (ja)	2012-05-23
PE20060172A1 (es)	2006-03-31
AU2005238144A1 (en)	2005-11-10
UA87306C2 (en)	2009-07-10
RU2006141246A (ru)	2008-06-10
CY1108087T1 (el)	2014-02-12
HRP20080099T3 (en)	2008-03-31
CA2563401C (en)	2012-08-07

Publication	Publication Date	Title
ZA200702394B (en)	2008-11-26	Indozolone derivatives as 11b-HSD1 inhibitors
ZA200700181B (en)	2009-03-25	Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
IL194582A0 (en)	2009-08-03	Condensed imidazole derivatives as aromatase inhibitors
ZA200903286B (en)	2010-10-27	Hydantoin derivatives used as MMP Inhibitors
IL198247A0 (en)	2009-12-24	Indazole derivatives useful as l-cpt1 inhibitors
IL193482A0 (en)	2009-05-04	Hydantoin based kinase inhibitors
IL178672A0 (en)	2007-02-11	Imidazole derivatives used as tafia inhibitors
ZA200610771B (en)	2008-08-27	Quinazolinedolone derivatives as PARP inhibitors
IL197955A0 (en)	2009-12-24	Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes
IL189194A0 (en)	2008-06-05	Substituted benzimidazoles as kinase inhibitors
IL183599A0 (en)	2007-09-20	Novel hydantoin derivatives as metalloproteinase inhibitors
ZA200904175B (en)	2010-04-28	Imidazole derivatives as kinesin spindle protein inhibitors (EG-5)
ZA200705076B (en)	2008-12-31	Novel hydantoin derivatives as metalloproteinase inhibitors
ZA200705068B (en)	2008-10-29	Hydantoin derivatives useful as metalloproteinase inhibitors
IL196000A0 (en)	2009-09-01	2-arylindole derivatives as npges-i inhibitors
PT1763517E (pt)	2011-07-01	Derivados de pirimidina como inibidores 11beta-hsd1
PL1912972T3 (pl)	2012-02-29	Podstawione związki imidazolowe jako inhibitory KSP
PL2104497T3 (pl)	2015-07-31	Pochodne sulfamidu jako inhibitory TAFIa
IL184559A0 (en)	2007-10-31	Imidazole derivatives
SI1937673T1 (sl)	2016-02-29	Imidazolovi derivati kot inhibitorji TAFIa
ZA200608998B (en)	2008-07-30	Imidazole derivatives as tyrosine kinase inhibitors
ZA200806993B (en)	2009-09-30	Hydantoin based kinase inhibitors
HK1122805A (en)	2009-05-29	Condensed imidazole derivatives as aromatase inhibitors